Ten human volunteers were immunized intravenously with ethanol-soluble common enterobacterial antigen (CA) obtained from Escherichia coli 0111. The immunogen contained 6 mg/ml, excluding salts. The antigen was given in amounts of 2 ml each in dilutions of 1:250 (48 Mg) and 1:125 (96 Mg), respectively, 1 week apart. Serum specimens were obtained prior to immunization and 1 week after the last injection. The CA hemagglutinins were titrated by means of the passive hemagglutination test, with CA from E. coli 014 as indicator antigen. The injections were well tolerated without side-effects by all subjects. A significant (> fourfold) increase in the titers of CA hemagglutinins was observed following immunization in 9 out of 10 volunteers. These results indicate the feasibility of immunization with CA of human subjects and suggest exploration of immunization against infection caused by Enterobacteriaceae producing this common enterobacterial antigen.
Numerous enteric bacteria possess a common antigen (CA), first described by Kunin et al. (4) . In the rabbit, antibodies specific for CA are engendered by intravenous immunization with either Escherichia coli 014 and a few other enteric bacteria or with the ethanol-soluble fraction of most Enterobacteriaceae (5, 6) . Such antibodies promote phagocytosis by rabbit peritoneal polymorphonuclear leukocytes of strains possessing CA, regardless of the strain from which immunogenic CA is derived (1) . The possibility exists, therefore, that immunization with CA affords protection against infection by enteric bacteria sharing this antigenic determinant. Indeed, Domingue et al. (2) reported that both active and passive immunization of rabbits against experimental pyelonephritis, and Gorzynski et al. (3) showed that passive immunization results in slight, transient protection of mice against experimental Salmonella infection. The present investigation is concerned with the hemagglutinin response of human subjects to immunization with small amounts of CA.
The ethanol-soluble fraction of E. coli 0111, prepared in accord with the previously described method (5), was used to immunize 10 healthy volunteers. The immunogen contained approximately 6 mg per ml, excluding salts, and was distributed in ampoules. After autoclaving (20 min, 121 C), the ampoules were flame-sealed and stored at -20 C. The antigen was thawed immediately prior to use. Ten healthy volunteers were given two intravenous injections of antigen (2 ml) 1 week apart. The antigen was used in dilutions of 1:250 and 1:125, respectively, and contained 48 ,ug for the first injection and 96 ,ug for the second.
Serum specimens, obtained prior to immunization and 1 week following the last dose, were stored at -20 C until used.
The CA antibody titers of the sera were determined by the previously described passive hemagglutination test (7) . Briefly, serum in twofold serial dilutions (0.2 ml) was mixed with human erythrocytes of blood group 0 (2.5 % suspension, 0.2 ml) after the latter had been modified with CA from E. coli 014 (supernatant fraction of heated culture in dilution of 1:10). The mixtures were incubated for 30 min at 37 C, and the hemagglutination was read grossly after centrifugation at 1,300 X g for 2 min. A CA antibody response was considered to be present only if the antibody titers between preimmunization and postimmunization serum specimens increased at least fourfold in tests done simultaneously. The specificity of the antibody was documented by means of the hemagglutination-inhibition test, as described previously (7). Briefly, serum was incubated for 30 min at 37 C with CA from S. typhimurium as inhibitor or with buffer for control purposes and was then tested with CA-modified erythrocytes as described above. Absence of hemagglutination in the presence of the inhibitor was considered as INFECT. IMMUNITY In the amounts used (48-and 96-,ug, respectively), the immunogen was well tolerated by all 10 volunteers. It is particularly noteworthy that febrile reactions were not encountered. The results of the antibody studies of these 10 human subjects are shown in Table 1 . It may be seen that all volunteers but one responded with the production of hemagglutinins to significant levels, the increase in antibody titers being eightfold or greater in 9 out of 10 individuals. Hemagglutinationinhibition tests confirmed the specificity of the CA antibody response.
Since most smooth strains of Enterobacteriaceae, as first described by Kunin et al. (4) , share a common antigen and since antibodies to this antigen opsonize enteric bacteria for phagocytosis by rabbit peritoneal polymorphonuclear leukocytes (1), the possibility presents itself that immunization, either active or passive, provides protection against infection by these microorganisms.
Immunization with a single antigen or a single antiserum may have clinical promise in view of the seriousness of certain enterobacterial infections in man, particularly in infants and also in patients suffering from debilitating diseases such as malignancy. The present study has revealed that CA prepared from E. coli 0111 by ethanol fractionation (5) yields a product that was well tolerated following intravenous administration in adult volunteers in the dosages used. In addition, a significant hemagglutinin response was documented in 9 out of 10 subjects. These results suggest exploring the possible usefulness of this immunogen in selected patients subject to serious infections caused by various Enterobacteriaceae.
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